Semaglutide

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It is FDA-approved as Ozempic for type-2 diabetes, Wegovy for weight management, and Rybelsus as an oral formulation.

Mechanism

• GLP-1 receptor agonism. Slows gastric emptying, reduces appetite via central nervous system pathways, enhances glucose-dependent insulin secretion.

Common research protocols

Dosing information below reflects published research literature. It is not medical advice and is not a treatment plan.

• FDA-approved weight management dosing. Weekly subcutaneous injection, titrated from 0.25 mg through 2.4 mg over 16-20 weeks.
• Titration. Standard escalation: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg at 4-week intervals.

Evidence at a glance

• Human data. STEP-1 trial (Wilding et al., 2021, NEJM): mean weight reduction of approximately 14.9% at 2.4 mg over 68 weeks.
• Cardiovascular outcomes. SELECT trial (2023) reported reduced major adverse cardiovascular events in overweight/obese adults with established cardiovascular disease.
• Known side effects. Nausea, vomiting, diarrhea, constipation. Rare: pancreatitis, gallbladder events.

Reconstitution & handling

Lyophilized peptides ship as freeze-dried powder. Reconstitute with bacteriostatic water; refrigerate the reconstituted vial. Use the reconstitution calculator to get syringe-unit readings for your target dose. General reconstitution and syringe guidance in the How It Works page.

Primary-literature list for this guide available on request via contact.